RO7293583 + obinutuzumab

RO7293583 + obinutuzumab is an investigational **combination therapy** for cancer, particularly being studied in unresectable metastatic tyrosinase related protein 1 (TYRP1)-positive melanoma. **RO7293583** is a novel TYRP1-targeting CD3 T-cell engager, designed as a bispecific monoclonal antibody that binds both TYRP1 on melanoma cells and CD3 on T-cells, thereby redirecting T-cell cytotoxicity toward the tumor[5]. **Obinutuzumab** is a fully humanized, glycoengineered type II anti-CD20 monoclonal antibody, approved for chronic lymphocytic leukemia and follicular lymphoma, that works by inducing direct cell death and mediating antibody-dependent cell cytotoxicity and phagocytosis[1][2][4]. In the studied regimen, obinutuzumab is used as **pre-treatment** to mitigate immune-related adverse events and enhance the activity of RO7293583[3][5].

Other names

GA101GA-101GA 101